Sanochemia acquires majority shareholding in AlcaSynn
In the course of a venture capital transaction, Sanochemia Pharmazeutika AG has acquired a 60% holding in Innsbruck-based AlcaSynn Pharmaceuticals GmbH. Through its stake in this company, founded in 2002 by Prof. Dr. Helmut Schmidhammer and Dr. Johannes Schütz, Sanochemia has secured access to a broad technological base and extensive developmental resources in the fields of pain management and CNS.
In cooperation with leading pharmaceutical players, AlcaSynn develops drugs on the basis of synthetic morphinan derivatives with a marked pharmacological profile for the treatment of pain, inflammation, Parkinson's and Alzheimer's. The company is headed by Dr. Peter Kayatz (CEO) and Dr. Mariana Spetea (CSO) and currently holds a patent portfolio consisting of 13 awarded patents and a further 26 patents pending.
The leading product candidate, AS006, is a strong, peripherally-acting painkiller (100 times stronger than morphine) which does not exhibit the adverse side effects characteristic of other opiates including respiratory depression, drowsiness and potential addiction. AS006 is currently in pre-clinical testing with clinical trials scheduled to begin in 2008.
Sanochemia's shareholding in AlcaSynn Pharmaceuticals GmbH represents a major strategic addition to its potential as a provider of specialty pharmaceuticals in its existing development segments. Key for Sanochemia is the synergy potential offered by utilising its synthesis plant located in Neufeld, Austria.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.
Topic world Synthesis
Chemical synthesis is at the heart of modern chemistry and enables the targeted production of molecules with specific properties. By combining starting materials in defined reaction conditions, chemists can create a wide range of compounds, from simple molecules to complex active ingredients.